Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 4/2013

01.12.2013 | short review

ASCO 2013: news in early-stage and advanced breast cancer

verfasst von: Günther G. Steger, Rupert Bartsch

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Recent advances in the field of systemic treatment resulted in a significant decline of overall breast cancer mortality. Numerous important issues, however, remain unresolved. Among others, the optimal duration and sequence of endocrine therapy in the adjuvant setting are much debated. Furthermore, the advance of novel targeted treatment options in human epidermal growth factor receptor 2-positive and hormone-receptor-positive breast cancers resulted in an urgent need for establishing reliable predictive markers. Finally, in triple-negative breast cancer, there are currently no specific biologically targeted therapies available.
At the 2013 American Society of Clinical Oncology’s Annual Meeting, a number of studies were presented providing novel insights in several of those fields of research. This article reviews potentially relevant abstracts and aims to set the data into the context of current knowledge.
Literatur
1.
Zurück zum Zitat Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C, Valagussa P, Baselga J. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375(9712):377–84.PubMedCrossRef Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C, Valagussa P, Baselga J. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375(9712):377–84.PubMedCrossRef
2.
Zurück zum Zitat Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhov MJ, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Magazzu D, Steinseifer J, Valagussa P, Baselga J. Follow-up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT + H) followed by adjuvant H versus CT alone, in patients with HER2-positive locally advanced breast cancer. J Clin Oncol. 2013;31(Suppl. 15):#503. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhov MJ, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Magazzu D, Steinseifer J, Valagussa P, Baselga J. Follow-up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT + H) followed by adjuvant H versus CT alone, in patients with HER2-positive locally advanced breast cancer. J Clin Oncol. 2013;31(Suppl. 15):#503.
3.
Zurück zum Zitat Carey LA, Berry DA, Ollila D, Harris L, Krop IE, Weckstein D, Henry NL, Anders CK, Cirrincione C, Winer EP, Perou CM, Hudis C. CALGB 40601: phase III trial of lapatinib added to neoadjuvant therapy of HER2 + breast cancer. J Clin Oncol. 2013;31(Suppl.15):#500. Carey LA, Berry DA, Ollila D, Harris L, Krop IE, Weckstein D, Henry NL, Anders CK, Cirrincione C, Winer EP, Perou CM, Hudis C. CALGB 40601: phase III trial of lapatinib added to neoadjuvant therapy of HER2 + breast cancer. J Clin Oncol. 2013;31(Suppl.15):#500.
4.
Zurück zum Zitat Minckwitz G, Schneeweiss A, Salat C, Rezai M, Zahm DM, Klare P, Blohmer JU, Tesch H, Khandan F, Jud S, Jackisch C, Mehta K, Loibl S, Untch M, The German Breast Group. A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). J Clin Oncol. 2013;31(Suppl. 15):#1004. Minckwitz G, Schneeweiss A, Salat C, Rezai M, Zahm DM, Klare P, Blohmer JU, Tesch H, Khandan F, Jud S, Jackisch C, Mehta K, Loibl S, Untch M, The German Breast Group. A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). J Clin Oncol. 2013;31(Suppl. 15):#1004.
5.
Zurück zum Zitat Shulman LN, Berry DA, Cirrincione CT, Becker H, Perez EA, O’Regan R, Martino S, Shapiro CL, Atkins J, Schneider C, Kimmick GG, Burstein HJ, Norton L, Muss HB, Hudis C, Winer EP. Comparison of doxorubicin and cyclophosphamide (AC) versus single-agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0–3 positive axillary nodes: CALGB 40101. J Clin Oncol. 2013;31(Suppl.15):#1007. Shulman LN, Berry DA, Cirrincione CT, Becker H, Perez EA, O’Regan R, Martino S, Shapiro CL, Atkins J, Schneider C, Kimmick GG, Burstein HJ, Norton L, Muss HB, Hudis C, Winer EP. Comparison of doxorubicin and cyclophosphamide (AC) versus single-agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0–3 positive axillary nodes: CALGB 40101. J Clin Oncol. 2013;31(Suppl.15):#1007.
6.
Zurück zum Zitat Gray RG, Rea D, Handley K, Bowden SJ, Perry P, Earl HM, Poole CJ, Bates T, Chetiyawardana S, Dewar JA, Fernando IN, Grieve R, Nicoll J, Rayter Z, Robinson A, Salman A, Yarnold J, Bathers S, Marshall A, Lee M, on behalf of the aTTom Collaborative Group. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol. 2013; 31(Suppl.15):#5. Gray RG, Rea D, Handley K, Bowden SJ, Perry P, Earl HM, Poole CJ, Bates T, Chetiyawardana S, Dewar JA, Fernando IN, Grieve R, Nicoll J, Rayter Z, Robinson A, Salman A, Yarnold J, Bathers S, Marshall A, Lee M, on behalf of the aTTom Collaborative Group. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol. 2013; 31(Suppl.15):#5.
7.
Zurück zum Zitat Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R, for the Adjuvant Tamoxifen, Longer Against Shorter (ATLAS) Collaborative Group.  Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2012; 9869(12):805–16. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R, for the Adjuvant Tamoxifen, Longer Against Shorter (ATLAS) Collaborative Group.  Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2012; 9869(12):805–16.
8.
Zurück zum Zitat Gnant M, Dowsett M, Filipits M, Lopez-Knowles E, Greil R, Balic M, Cowens JW, Nielsen TO, Shaper C, Sestak I, Fesl C, Cuzick JM. Identifying clinically relevant prognostic subgroups in node-positive postmenopausal HR + early breast cancer patients treated with endocrine therapy: a combined analysis of 2,485 patients from ABCSG-8 ad ATAC using the PAM50 risk of recurrence (ROR) score and intrinsic subtype. J Clin Oncol. 2013; 31 (Suppl 15):#506. Gnant M, Dowsett M, Filipits M, Lopez-Knowles E, Greil R, Balic M, Cowens JW, Nielsen TO, Shaper C, Sestak I, Fesl C, Cuzick JM. Identifying clinically relevant prognostic subgroups in node-positive postmenopausal HR + early breast cancer patients treated with endocrine therapy: a combined analysis of 2,485 patients from ABCSG-8 ad ATAC using the PAM50 risk of recurrence (ROR) score and intrinsic subtype. J Clin Oncol. 2013; 31 (Suppl 15):#506.
9.
Zurück zum Zitat Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520–9.PubMedCrossRef Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520–9.PubMedCrossRef
10.
Zurück zum Zitat Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaëth D, Legouffe E, Allouache D, El Kouri C, Pujade-Lauraine E. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol. 2012;30(22):2718–24.PubMedCrossRef Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaëth D, Legouffe E, Allouache D, El Kouri C, Pujade-Lauraine E. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol. 2012;30(22):2718–24.PubMedCrossRef
11.
Zurück zum Zitat Hortobagyi GN, Piccart-Gebhart MJ, Rugo HS, Burris HA, Campone M, Noguchi S, Perez AT, Deleu I, Shtivelband M, Provencher L, Masuda N, Dakhil SR, Anderson I, Chen D, Damask A, Huang A, McDonald R, Taran T, Sahmoud T, Baselga J, at al. Correlation of molecular alterations with efficacy of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer: results from BOLERO-2. J Clin Oncol. 2013;31(Suppl.15):#509. Hortobagyi GN, Piccart-Gebhart MJ, Rugo HS, Burris HA, Campone M, Noguchi S, Perez AT, Deleu I, Shtivelband M, Provencher L, Masuda N, Dakhil SR, Anderson I, Chen D, Damask A, Huang A, McDonald R, Taran T, Sahmoud T, Baselga J, at al. Correlation of molecular alterations with efficacy of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer: results from BOLERO-2. J Clin Oncol. 2013;31(Suppl.15):#509.
12.
Zurück zum Zitat Treilleux I, Arnedos M, Cropet C, Ferrero JM, Lacourtoisie SA, Spaeth D, Levy C, Legouffe E, Pujade-Lauraine E, Wang Q, Bachelot T. Predictive markers of everolimus efficacy in hormone receptor positive (HR + ) metastatic breast cancer (MBC): final results of the TAMRAD trial translational study. J Clin Oncol. 2013;31(Suppl.15):#510. Treilleux I, Arnedos M, Cropet C, Ferrero JM, Lacourtoisie SA, Spaeth D, Levy C, Legouffe E, Pujade-Lauraine E, Wang Q, Bachelot T. Predictive markers of everolimus efficacy in hormone receptor positive (HR + ) metastatic breast cancer (MBC): final results of the TAMRAD trial translational study. J Clin Oncol. 2013;31(Suppl.15):#510.
13.
Zurück zum Zitat Johnston RD, Basik M, Hegg R, Lausoontornsiri W, Grzeda L, Clemons M, Dreosti LM, Ghiorghiu S, Mann H, Landers D, Stuart M, Cristofanilli M. Phase II randomized study of the EGFR, HER2, HER3 signaling inhibitor AZD8931 in combination with anastrozole (A) in women with endocrine therapy (ET) naive advanced breast cancer (MINT). J Clin Oncol. 2013;31(Suppl.15):#531. Johnston RD, Basik M, Hegg R, Lausoontornsiri W, Grzeda L, Clemons M, Dreosti LM, Ghiorghiu S, Mann H, Landers D, Stuart M, Cristofanilli M. Phase II randomized study of the EGFR, HER2, HER3 signaling inhibitor AZD8931 in combination with anastrozole (A) in women with endocrine therapy (ET) naive advanced breast cancer (MINT). J Clin Oncol. 2013;31(Suppl.15):#531.
14.
Zurück zum Zitat Hanker LC, Hitschold T, Hesse T, Grafe A, Foerster FG, Schroeder JK, Janssen J, Reichert DA, Hielscher C, Greinemann J, Borquez DJ, Schmidt M. Efficacy of trastuzumab re-therapy in routine treatment of HER2-positive breast cancer patients who relapsed after completed (neo-)adjuvant anti-HER2 therapy. J Clin Oncol. 2013;31(Suppl.15):#602. Hanker LC, Hitschold T, Hesse T, Grafe A, Foerster FG, Schroeder JK, Janssen J, Reichert DA, Hielscher C, Greinemann J, Borquez DJ, Schmidt M. Efficacy of trastuzumab re-therapy in routine treatment of HER2-positive breast cancer patients who relapsed after completed (neo-)adjuvant anti-HER2 therapy. J Clin Oncol. 2013;31(Suppl.15):#602.
15.
Zurück zum Zitat Clynes R, Knutson KL, Ballman KV, Erskine CL, Norton N, Sumrall SV, Northfelt DW, Tan W, Calfa CJ, Pegram MD, Perez EA. Combination trastuzumab and chemotherapy to induce immunity to multiple tumor antigens in patients with HER2-positive metastatic breast cancer: NCCTG (Alliance) studies N0337 and N98-32-52. J Clin Oncol. 2013;31(Suppl.15):#521. Clynes R, Knutson KL, Ballman KV, Erskine CL, Norton N, Sumrall SV, Northfelt DW, Tan W, Calfa CJ, Pegram MD, Perez EA. Combination trastuzumab and chemotherapy to induce immunity to multiple tumor antigens in patients with HER2-positive metastatic breast cancer: NCCTG (Alliance) studies N0337 and N98-32-52. J Clin Oncol. 2013;31(Suppl.15):#521.
16.
Zurück zum Zitat Bartsch R, Berghoff AS, Bago-Horvath Z, Preusser M, Steger GG, Rudas M, Birner P, Zielinski C. Coexpression of HER3 as a predictor of survival in HER2-positve breast cancer patients. J Clin Oncol. 2013;31(Suppl.15):#611. Bartsch R, Berghoff AS, Bago-Horvath Z, Preusser M, Steger GG, Rudas M, Birner P, Zielinski C. Coexpression of HER3 as a predictor of survival in HER2-positve breast cancer patients. J Clin Oncol. 2013;31(Suppl.15):#611.
17.
Zurück zum Zitat Park YH, Jung HA, Chang WJ, Choi MK, Hong JY, Ok OM, Seo JJ, Choi YL, Do I, Ahn JS, Im YH. Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) patients who received taxane plus trastuzumab treatment. J Clin Oncol. 2013;31(Suppl.15):#637. Park YH, Jung HA, Chang WJ, Choi MK, Hong JY, Ok OM, Seo JJ, Choi YL, Do I, Ahn JS, Im YH. Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) patients who received taxane plus trastuzumab treatment. J Clin Oncol. 2013;31(Suppl.15):#637.
18.
Zurück zum Zitat Bachelot T, Romieu G, Campone M, Diéras V, Cropet C, Dalenc F, Jimenez M, Le Rhun E, Pierga JY, Gonçalves A, Leheurteur M, Domont J, Gutierrez M, Curé H, Ferrero JM, Labbe-Devilliers C. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14(1):64–71.PubMedCrossRef Bachelot T, Romieu G, Campone M, Diéras V, Cropet C, Dalenc F, Jimenez M, Le Rhun E, Pierga JY, Gonçalves A, Leheurteur M, Domont J, Gutierrez M, Curé H, Ferrero JM, Labbe-Devilliers C. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14(1):64–71.PubMedCrossRef
19.
Zurück zum Zitat Morikawa A, Peereboom DM, Smith QR, Thorsheim H, Lockman PR, Simmons AJ, Weil RJ, Tabar V, Steeg PS, Seidman AD. Clinical evidence for drug penetration of capecitabine and lapatinib uptake in resected brain metastases from women with metastatic breast cancer. J Clin Oncol. 2013;31(Suppl.15):#514. Morikawa A, Peereboom DM, Smith QR, Thorsheim H, Lockman PR, Simmons AJ, Weil RJ, Tabar V, Steeg PS, Seidman AD. Clinical evidence for drug penetration of capecitabine and lapatinib uptake in resected brain metastases from women with metastatic breast cancer. J Clin Oncol. 2013;31(Suppl.15):#514.
20.
Zurück zum Zitat O’Regan AM, Ozguroglu M, Andre F, Toi M, Jerusalem GHM, Wilks S, Isaacs C, Xu B, Masuda N, Arena FP, Yardley DA, Yap YS, Mukhopadhyay P, Douma S, El-Hashimy M, Taran T, Sahmoud T, Lebwohl DE, Gianni L. Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3). J Clin Oncol. 2013;31(Suppl.15):#505. O’Regan AM, Ozguroglu M, Andre F, Toi M, Jerusalem GHM, Wilks S, Isaacs C, Xu B, Masuda N, Arena FP, Yardley DA, Yap YS, Mukhopadhyay P, Douma S, El-Hashimy M, Taran T, Sahmoud T, Lebwohl DE, Gianni L. Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3). J Clin Oncol. 2013;31(Suppl.15):#505.
21.
Zurück zum Zitat Inbar MJ, Lang I, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Ahlers S, Brodowicz T, Zielinski C, Central European Cooperative Oncology Group. Efficacy of first-line bevacizumab (BEV)-based therapy for metastatic triple-negative breast cancer (TNBC):subgroup analysis of TURANDOT. J Clin Oncol. 2013;31(Suppl.15):#1040. Inbar MJ, Lang I, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Ahlers S, Brodowicz T, Zielinski C, Central European Cooperative Oncology Group. Efficacy of first-line bevacizumab (BEV)-based therapy for metastatic triple-negative breast cancer (TNBC):subgroup analysis of TURANDOT. J Clin Oncol. 2013;31(Suppl.15):#1040.
22.
Zurück zum Zitat Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12(9):852–61.PubMedCrossRef Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12(9):852–61.PubMedCrossRef
23.
Zurück zum Zitat Somlo G, Frankel PH, Luu TH, Ma C, Arun B, Garcia A, Cigler T, Fleming GF, Harvey HA, Sparano JA, Nanda R, Chew HK, Moynihan TJ, Vahdat LT, Goetz MP, Hurria A, Mortimer JE, Gandara DR, Chen AP, Weitzel JN. Efficacy of the combination of ABT-888 (veliparib) and carboplatin in patients with BRCA-associated breast cancer. J Clin Oncol. 2013;31(Suppl.15):#1024. Somlo G, Frankel PH, Luu TH, Ma C, Arun B, Garcia A, Cigler T, Fleming GF, Harvey HA, Sparano JA, Nanda R, Chew HK, Moynihan TJ, Vahdat LT, Goetz MP, Hurria A, Mortimer JE, Gandara DR, Chen AP, Weitzel JN. Efficacy of the combination of ABT-888 (veliparib) and carboplatin in patients with BRCA-associated breast cancer. J Clin Oncol. 2013;31(Suppl.15):#1024.
Metadaten
Titel
ASCO 2013: news in early-stage and advanced breast cancer
verfasst von
Günther G. Steger
Rupert Bartsch
Publikationsdatum
01.12.2013
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-013-0119-3

Weitere Artikel der Ausgabe 4/2013

memo - Magazine of European Medical Oncology 4/2013 Zur Ausgabe